177 related articles for article (PubMed ID: 33741192)
1. Cost-effectiveness of pediatric norovirus vaccination in daycare settings.
Steimle LN; Havumaki J; Eisenberg MC; Eisenberg JNS; Prosser LA; Pike J; Ortega-Sanchez IR; Mattison CP; Hall AJ; Steele MK; Lopman BA; Hutton DW
Vaccine; 2021 Apr; 39(15):2133-2145. PubMed ID: 33741192
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of norovirus vaccination in children in Peru.
Mirelman AJ; Ballard SB; Saito M; Kosek MN; Gilman RH
Vaccine; 2015 Jun; 33(27):3084-91. PubMed ID: 25980428
[TBL] [Abstract][Full Text] [Related]
3. Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting.
Bartsch SM; O'Shea KJ; Wedlock PT; Ferguson MC; Siegmund SS; Lee BY
Am J Prev Med; 2021 Mar; 60(3):360-368. PubMed ID: 33516583
[TBL] [Abstract][Full Text] [Related]
4. Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.
de Boer PT; Backer JA; van Hoek AJ; Wallinga J
BMC Med; 2020 Jan; 18(1):11. PubMed ID: 31931789
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of a pentavalent rotavirus vaccine in Oman.
Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA
BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946
[TBL] [Abstract][Full Text] [Related]
8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
Meier G; Gregg M; Poulsen Nautrup B
J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
[TBL] [Abstract][Full Text] [Related]
10. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
Brydak L; Roiz J; Faivre P; Reygrobellet C
Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
[TBL] [Abstract][Full Text] [Related]
11. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
12. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
Milne RJ; Grimwood K
Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
[TBL] [Abstract][Full Text] [Related]
13. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
[TBL] [Abstract][Full Text] [Related]
14. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
15. Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis.
Wu JT; Jit M; Zheng Y; Leung K; Xing W; Yang J; Liao Q; Cowling BJ; Yang B; Lau EH; Takahashi S; Farrar JJ; Grenfell BT; Leung GM; Yu H
PLoS Med; 2016 Mar; 13(3):e1001975. PubMed ID: 26978565
[TBL] [Abstract][Full Text] [Related]
16. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of childhood rotavirus vaccination in Germany.
Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]